{"id":4664,"date":"2024-02-21T16:26:00","date_gmt":"2024-02-21T21:26:00","guid":{"rendered":"https:\/\/stillcoviding.ca\/en\/?p=4664"},"modified":"2024-02-22T21:14:14","modified_gmt":"2024-02-23T02:14:14","slug":"paxlovid-use-tied-to-84-lower-risk-of-hospital-care","status":"publish","type":"post","link":"https:\/\/stillcoviding.ca\/en\/news\/paxlovid-use-tied-to-84-lower-risk-of-hospital-care\/","title":{"rendered":"Paxlovid use tied to 84% lower risk of hospital care"},"content":{"rendered":"<p>University of North Carolina\u2013Chapel Hill investigators report today that COVID-19 hospitalization risk was reduced by 84% among Paxlovid (nirmatrelvir and ritonavir) recipients in a large, diverse healthcare system during January to August 2022, when the Omicron strain was dominant.<\/p>\n<p>The study appears in the Journal of Antimicrobial Chemotherapy. Paxlovid is authorized for use in US patients 12&nbsp;years and older at risk for developing severe outcomes from COVID-19 infections. In early clinical trials, the use of the antiviral drug was associated with a relative risk reduction of 89% of disease progression to severe illness.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>University of North Carolina\u2013Chapel Hill investigators report today that COVID-19 hospitalization risk was reduced by 84% among Paxlovid (nirmatrelvir and ritonavir) recipients in a large, diverse healthcare system during January to August 2022, when the Omicron strain was dominant.<\/p>\n<p>The study appears in the Journal of Antimicrobial Chemotherapy. Paxlovid is authorized for use in US patients 12&nbsp;years and older at risk for developing severe outcomes from COVID-19 infections. In early clinical trials, the use of the antiviral drug was associated with a relative risk reduction of 89% of disease progression to severe illness.<\/p>\n<div class=\"more-link-wrapper\"><a class=\"more-link\" href=\"https:\/\/stillcoviding.ca\/en\/news\/paxlovid-use-tied-to-84-lower-risk-of-hospital-care\/\">Continue reading<span class=\"screen-reader-text\">Paxlovid use tied to 84% lower risk of hospital care<\/span><\/a><\/div>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[473,18,474,8,14,51,921],"class_list":["post-4664","post","type-post","status-publish","format-standard","hentry","category-news","tag-antiviral-drugs","tag-covid-19","tag-paxlovid","tag-research","tag-sars-cov-2","tag-united-states","tag-university-of-north-carolina","entry"],"_links":{"self":[{"href":"https:\/\/stillcoviding.ca\/en\/wp-json\/wp\/v2\/posts\/4664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stillcoviding.ca\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stillcoviding.ca\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stillcoviding.ca\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stillcoviding.ca\/en\/wp-json\/wp\/v2\/comments?post=4664"}],"version-history":[{"count":2,"href":"https:\/\/stillcoviding.ca\/en\/wp-json\/wp\/v2\/posts\/4664\/revisions"}],"predecessor-version":[{"id":4666,"href":"https:\/\/stillcoviding.ca\/en\/wp-json\/wp\/v2\/posts\/4664\/revisions\/4666"}],"wp:attachment":[{"href":"https:\/\/stillcoviding.ca\/en\/wp-json\/wp\/v2\/media?parent=4664"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stillcoviding.ca\/en\/wp-json\/wp\/v2\/categories?post=4664"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stillcoviding.ca\/en\/wp-json\/wp\/v2\/tags?post=4664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}